BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 27800661)

  • 1. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
    Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
    Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
    Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
    Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
    Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
    Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
    Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
    Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
    J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma.
    Bini I; Asaftei SD; Riggi C; Tirtei E; Manicone R; Biasin E; Basso ME; Agnoletti G; Fagioli F
    Cardiol Young; 2017 Nov; 27(9):1815-1822. PubMed ID: 28780919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strain and left ventricular volumes for predicting cardiotoxicity: a life-saving approach in anthracycline cancer treatment?
    Bergler-Klein J
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):968-9. PubMed ID: 26206463
    [No Abstract]   [Full Text] [Related]  

  • 9. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study.
    Hamirani Y; Fanous I; Kramer CM; Wong A; Salerno M; Dillon P
    Med Oncol; 2016 Jul; 33(7):82. PubMed ID: 27334792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
    Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
    Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
    J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracyclinemediated cardiotoxicity.
    Mornoş C; Manolis AJ; Cozma D; Kouremenos N; Zacharopoulou I; Ionac A
    Hellenic J Cardiol; 2014; 55(3):235-44. PubMed ID: 24862616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
    Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
    BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials.
    D'Amario D; Laborante R; Bianchini E; Galli M; Ciliberti G; Mennuni M; Patti G
    Int J Cardiol; 2023 Nov; 391():131219. PubMed ID: 37527752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
    Cardinale D; Colombo A; Lamantia G; Colombo N; Civelli M; De Giacomi G; Rubino M; Veglia F; Fiorentini C; Cipolla CM
    J Am Coll Cardiol; 2010 Jan; 55(3):213-20. PubMed ID: 20117401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity.
    Charbonnel C; Convers-Domart R; Rigaudeau S; Taksin AL; Baron N; Lambert J; Ghez S; Georges JL; Farhat H; Lambert J; Rousselot P; Livarek B
    Eur Heart J Cardiovasc Imaging; 2017 Apr; 18(4):392-401. PubMed ID: 28064155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
    Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
    J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.